Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Solid Tumor

Interventions: Drug: oxaliplatin
Drug: pemetrexed disodium

First Posted Date: 2007-05-07

Last Posted Date: 2011-04-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT00470405

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: irinotecan hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2012-07-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00469898

Locations: 🇺🇸
Owensboro Medical Health System, Owensboro, Kentucky, United States
🇺🇸
Memorial Health Care System, Chattanooga, Tennessee, United States
🇺🇸
West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson, Tennessee, United States

and more 5 locations

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Not Applicable

Terminated

Conditions: Liver Cancer

Interventions: Procedure: quality-of-life assessment
Radiation: yttrium Y 90 resin microspheres

First Posted Date: 2007-05-07

Last Posted Date: 2012-09-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 12

Registration Number: NCT00469963

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: bevacizumab
Drug: erlotinib hydrochloride
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Other: immunologic technique
Other: laboratory biomarker analysis
Procedure: biopsy

First Posted Date: 2007-04-27

Last Posted Date: 2013-07-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 34

Registration Number: NCT00466687

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: celecoxib
Genetic: proteomic profiling
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: mass spectrometry

First Posted Date: 2007-04-27

Last Posted Date: 2012-12-19

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 17

Registration Number: NCT00466505

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: cetuximab
Drug: gemcitabine hydrochloride
Radiation: radiation therapy

First Posted Date: 2007-04-27

Last Posted Date: 2012-05-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 9

Registration Number: NCT00467116

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Phase 2

Terminated

Conditions: Pheochromocytoma
Head and Neck Cancer
Islet Cell Tumor
Metastatic Cancer

Interventions: Drug: octreotide acetate
Radiation: yttrium Y 90 resin microspheres

First Posted Date: 2007-04-27

Last Posted Date: 2012-05-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 10

Registration Number: NCT00466856

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: bortezomib
Drug: docetaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2007-01-23

Last Posted Date: 2011-11-16

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT00425750

Locations: 🇺🇸
Jennie Stuart Medical Center, Hopkinsville, Kentucky, United States
🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States
🇺🇸
Tennessee Plateau Oncology - Crossville, Crossville, Tennessee, United States

and more 4 locations

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: erlotinib hydrochloride

First Posted Date: 2006-12-28

Last Posted Date: 2013-04-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 16

Registration Number: NCT00416650

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: docetaxel
Genetic: protein expression analysis
Other: laboratory biomarker analysis
Procedure: biopsy
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2006-06-23

Last Posted Date: 2012-04-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 34

Registration Number: NCT00343512

Locations: 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy